QIAGEN (QGEN) has expanded its strategic partnership with Bio-Manguinhos/Fiocruz, a leading provider of vaccines and diagnostics to the Brazilian Ministry of Health. Since their initial collaboration in 2009, which provided reagents and instruments for testing HIV and hepatitis C, the partnership has now grown to include an advanced PCR-based molecular screening platform.

QIAGEN（QGEN）扩大了与Bio Manguinhos/Fiocruz的战略合作伙伴关系，Bio Manguinhos/Fiocruz是巴西卫生部疫苗和诊断的领先供应商。自2009年首次合作提供艾滋病毒和丙型肝炎检测试剂和仪器以来，该合作关系现已发展到包括一个先进的基于PCR的分子筛查平台。

The new capability will enable Bio-Manguinhos to detect malaria, alongside HIV, hepatitis B, and C viruses—an enhancement not previously available in Brazil's blood donation program. Additionally, the expanded partnership will support epidemiological surveillance of Brazil's ongoing dengue epidemic by providing dengue molecular kits developed with unique chemistry from QIAGEN and Bio-Manguinhos.

这项新功能将使Bio Manguinhos能够检测疟疾，以及艾滋病毒，乙型肝炎和丙型肝炎病毒，这是巴西献血计划以前没有的增强功能。此外，扩大的伙伴关系将通过提供由QIAGEN和Bio Manguinhos开发的登革热分子试剂盒，支持对巴西正在进行的登革热疫情进行流行病学监测。

QIAGEN noted that it will deliver essential molecular biology technologies, tailored solutions, and comprehensive training to bolster Brazil's public health efforts. For comments and feedback contact: editorial@rttnews.comBusiness News

QIAGEN指出，它将提供基本的分子生物学技术、量身定制的解决方案和全面的培训，以支持巴西的公共卫生工作。如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻

Biotech Stocks Facing FDA Decision In August 2024

2024年8月美国食品和药物管理局（FDA）决定生物技术股